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Abstract
Currently there is no effective treatment available for major neurodegenerative disorders
associated to protein misfolding, including Alzheimer’s and Parkinson's disease. One of
most promising therapeutic approaches under development focuses on inhibiting the mis-
folding and aggregation pathway. However, it is likely that by the time clinical symptoms
appear, there is a large accumulation of misfolded aggregates and a very substantial dam-
age to the brain. Thus, it seems that at the clinical stage of the disease it is necessary also
to develop strategies aiming to prevent the neuronal damage produced by already formed
misfolded aggregates. Chronic activation of calcineurin (CaN), a type IIB phosphatase, has
been implicated as a pivotal molecule connecting synaptic loss and neuronal damage to
protein misfolding. The fact that the crystal structure of CaN is also well established makes
it an ideal target for drug discovery. CaN activity assays for High Throughput Screening
(HTS) reported so far are based on absorbance. In this article we report the development of
a fluorescent quenching based CaN activity assay suitable for robotic screening of large
chemical libraries to find novel inhibitors. The assay yielded a Z score of 0.84 with coeffi-
cient of variance 15%. Our results also show that this assay can be used to identify CaN
inhibitors with a wide range of potencies.
Introduction
Neurodegenerative diseases (NDs) including Alzheimer’s Disease (AD), Parkinson’s Disease
(PD), Transmissible Spongiform Encephalopathies (TSEs) or Prion Diseases and Huntington’s
Disease (HD) are some of the most debilitating disorders, affecting abstract thinking, skilled
movements, emotional feelings, cognition, memory, and other abilities. Synaptic abnormalities,
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neuronal death and accumulation of misfolded protein aggregates are the hallmark features of
these diseases. Compelling evidence indicates that cerebral accumulation of at least one dis-
ease-specific misfolded and aggregated protein initiates the disease pathology [1,2]. Moreover,
it seems that the mechanism by which misfolded aggregates are associated with neurodegen-
eration is similar among distinct diseases, and involves large changes of intracellular Ca2+ [3,4].
The rapid and sustained increase of Ca2+ in the cytoplasm after exposure to protein aggregates,
produces hyper-activation of a key protein, termed calcineurin (CaN) [5,6]. CaN is the only
Ca2+ dependent protein phosphatase present in neurons [7]. Optimum CaN activity is crucial
for synaptic plasticity, memory and neuronal survival [8–10].
CaN is a Ca2+/Calmodulin (CM) dependent serine/threonine phosphatase present in all
mammalian tissues and especially abundant in neurons [10–12]. It is a heterodimeric protein
composed of a 61 KDa catalytic subunit (calcineurin A; CnA), and a 15 KDa regulatory subunit
(calcineurin B; CnB) [10,13]. The catalytic core of CaN shares 41% and 39% amino acid
sequence identity with Protein Phosphatase 1 and 2 (PP1 & PP2), respectively. However the
three regulatory domains in the carboxy-terminal of subunit A distinguish CaN from others
[10]. These domains are the CnB binding domain, the calmodulin-binding domain and the
auto-inhibitory domain (CnAI). In resting conditions, the auto-inhibitory domain blocks the
active site of the enzyme, resulting in very low activity. Ca2+-dependent binding of CM to the
CnA-CnB complex removes CnAI from the catalytic site and activates the enzyme in a Ca2+
concentration dependent manner [13][14]. Optimum CaN activity is crucial to maintain the
proper phosphorylation of different important targets in neurons [5,8,10,15]. However, chroni-
cally activated CaN shifts this balance towards the dephosphorylated state, severely affecting
the cell. We and others have demonstrated disease-associated CaN hyper-activation in cultured
cells, tissue slices and primary neuronal cultures upon exposure to misfolded proteins, such as
aggregated Aβ (AD), α-synuclein, (PD), and prions (TSEs) [6,16–18]. Significantly higher CaN
activity is reported in animal models of AD, TSEs, and HD and also in AD patients[6,19–21].
Phosphorylated cAMP response element binding protein (CREB), one of the CaN targets,
induces expression of different proteins required for synaptic plasticity and neural growth
[5,22]. Significantly lower levels of phosphorylated CREB, which cannot translocate to the
nucleus to activate target genes, have also been reported in animal models of AD and TSEs
[6,18] and in the hippocampus of AD patients [23]. Reduction of CaN activity was sufficient to
rescue the phosphorylation state of CREB in mouse models of both pathologies, which leads to
a striking improvement in memory and motor coordination [6,17,18,24]. Dephosphorylated
by CaN, Nuclear Factor of Activated T cells (NFAT) c4 has been shown to be consistently pres-
ent in the nucleus which is sufficient to produce dystrophic neurites and dendritic spine loss,
the two most important morphological abnormalities of neurons reported in neurodegenera-
tive diseases [25]. Consistent with this information, significantly higher nuclear localization of
NFAT 3 has been observed in the hippocampus of AD patients which is co-related with the
Mini-Mental State Exam scores (MMSE) for AD patients [26]. Hyper-activated CaN is not
only associated to synaptic alterations, but it is also suggested to induce neuronal apoptosis
through dephosphorylation of BAD in AD and TSEs [27]. Interestingly proper the phosphory-
lation state can be recovered by pharmacological reduction of CaN activity, in a mouse model
of AD [18]. In fact, our own data indicate that pharmacological reduction of CaN activity not
only rescues the behavioral phenotype, it also significantly increases the lifespan in a mouse
model of TSEs [6].
The dual involvement of CaN on synaptic modulation and neural death (two of the main
problems in NDs) makes it an ideal candidate for therapeutic intervention in NDs associated
with protein misfolding. FDA approved CaN inhibitors, FK506 and cyclosporine (CyA), are
currently used to prevent the immune response after organ transplants [13,28]. Neither of
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these drugs bind directly to CaN. Instead they bind to their cognate immunophilins, FKBP12
(for FK506) and cyclophilin (for CyA) respectively. The resulting complexes bind to CaN,
inhibiting the substrate entry to the active site. This inhibition results in suppression of both
humoral and cellular immune responses. However, long-term use of FK506 or CyA is reported
to produce undesirable side effects, including nephrotoxicity, hypertension, hypercholesterol-
emia (for CyA only), diabetes and tremors (for FK506 only). Some of these side effects are
attributed to the drug binding to immunophilins [29,30]. This is the major limitation for using
these drugs (FK506 and CyA) for the treatment of neurodegenerative diseases. In addition, low
penetration across the blood-brain barrier [31] requires large doses of these drugs to be admin-
istered in animals in order to observe therapeutic effects in the brain, dangerously increasing
the extent and severity of undesirable side effects. Therefore, the search for a specific inhibitor
for CaN seems promising as a feasible therapy. CaN inhibition assays developed so far for HTS
are absorbance based [32,33]. Although absorbance assays are simple and robust, the reading
depends on the path length, requiring higher assay volume even in a 384 well format. Thus the
cost of screening/well increases seriously limiting the use of this assay in HTS. On the other
hand, fluorescent assays are more sensitive and work well with volumes<10 μL, which is ideal
for an HTS assay. Here, we describe the development of a robust high-throughput fluorescent
quenching based assay to screen for small molecule inhibitors for CaN as well as the results of a
pilot screen using this assay.
Methods
Reagents
Recombinant human calcineurin (Cat No. 539568), calmodulin (Cat No.208694), and
enodthall (Cat No. 324760) were purchased from EMDMillipore. Substrate RII Phosphopep-
tide was purchased from American Peptide (Product No. 310258). Developing reagent Mala-
chite green was purchased from BioAssay System, (Cat No. POMG-25H). The rest of the
chemical reagents including HEPES, DTT, MnCl2, CaCl2 were all purchased from Sigma.
White proxi-plates were purchased from PerkinElmer (Cat No. 6008280).
Enzyme Assay
Enzyme master mix was prepared in 2X assay buffer containing 100 mMHEPES, 1 mMDTT,1
mM CaCl2, 2mMMnCl2. CaN and CM were incubated in equimolar ratio (if not otherwise
mentioned) for 30 minutes at room temperature. Equal volumes of master mix and substrate
were mixed to initiate the reaction. Reaction was stopped by adding malachite green reagent
after 40 minutes. Absorbance of the end-product was measured at 620 nm using Molecular
Devices’ Gemini Spectromax spectrophotometer. For enzyme characterization, reaction vol-
ume was 50 μL and malachite green volume was 40 μL. For the HTS assay, reaction volume
was 5μL and malachite green was 2.5μL if not otherwise mentioned. Substrate was prepared by
dissolving in RIIP MilliQ water. For Km determination, different concentrations of RIIP were
prepared by serial dilution of 4 mM stock in Mili Q water For the pH titration, instead of
HEPES a mixture of 50mMMES, 100mM Tris was used. The buffer was adjusted to different
pH using acetic acid. The equation used to fit Km determination curve and CM titration curve
was the following:
v ¼ vmax½s
Km þ ½s 1þ ½sKi
   ð1Þ
Where: v = initial velocity, vmax =maximum velocity, [s] = substrate concentration, Ki = substrate
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inhibition constant.
Y ¼ Bmax½CM
h
ðICh50 þ ½CMhÞ
ð2Þ
Where: Bmax =Maximum CaN activity, [CM] = CM concentration. h = Hill cofactor.
Miniaturization of Assay
Colorimetric CaN activity was converted to fluorescence quenching based assay by modifying
a technique, previously described by Zuck and colleagues [34]. Quenching of background fluo-
rescence from white proxi-plates (Perkin Elmer, cat# 6008280) by phospho-malachite green
complex was determined. We first tested the maximum background fluorescence emission of
white-proxi plates at 610nm by exciting the plate at different excitation wavelengths using
Gemini SpectroMax EM fluorimeter. Finally, we chose excitation at 573nm since it produced
maximum emission at 610nm. We also observed that maximum emission changes depending
on the plate types used. In the presence of different assay solutions, the plate was excited at
573nm and fluorescence was measured at 610nm. Samples quenched the intrinsic fluorescence
of the plate. The highest concentration of phospho-malachite green quenched the most. Mala-
chite green control with no phosphate quenched the least. The fluorescence output from the
quenching assay was converted into OD using the following equation to prepare the phosphate
standard curve:
OD ¼  log signal from test well
average signal from blank
 
ð3Þ
[34]
HTS assay
The HTS assay was designed in a similar way as described by Glicksman and colleagues before
[35]. 384-well v-bottom polypropylene plates (Perkin Elmer) containing 0.4 μL of compound
at a concentration of 1.67 mM in DMSO in columns 1–22 or DMSO alone in 23, 24 were used
as compound source plate. 13 μL of assay buffer was added using a Multidrop Combi liquid
dispenser (Thermo Scientific), resulting in an intermediate concentration of 50 μM for each
compound. Enzyme master mixture (5nM CaN and 5nM CM), substrate (250μMRIIP) and
malachite green were transferred to respective 384 source plates (15μl/well). This volume was
calculated for 4 assay plates. 1 μL of compound solution was transferred from the compound
source plate to the assay plate (Perkin Elmer proxiplates,cat# 6008280) using the Biomek NX
automated liquid handling system with a 384-channel pipetting head (Beckman-Coulter, Brea,
CA) followed by addition of 2ul of enzyme master mixture in column 1–23 and only assay
buffer in column 24. The mixture was incubated for 30 minute at room temperature. The reac-
tion was initiated by adding 2μL substrate using a Biomek NX automated liquid handling sys-
tem from the substrate source plate. Final compound concentration in the assay was 10μM and
DMSO 0.6%. The reaction was terminated by adding 2.5μL of malachite green after 1 hour
using Biomek NX automated liquid handling system and the fluorescence was measured using
Geminai Spectromax fluorometer (ex:573nm; em:610nm).
Inhibition Assay
For the fluorescence quenching based inhibition assay, 1.86 mg of endothall (EMD; cat #
324760) was dissolved in 1 ml MilliQ water to prepare a 10 mM stock. The stock solution was
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serially diluted to 9.5 μM in MilliQ water. 1 μL from each stock was incubated with 2μL of the
master mix for 30 minutes followed by the enzyme reaction initiated by 2μL substrate addition.
For confirmation of hits does response inhibition was measured in 96 well absorbance based
format, using the same conditions as mentioned in the enzyme assay section. Stock solutions of
the candidates were prepared in DMSO. Serial dilutions of the compounds were prepared in
1X assay buffer keeping the DMSO concentration constant at 0.5%. 20μL of 2X enzyme master
mix was incubated with 10μL of the compounds at different concentrations for 30 minute at
room temperature. The reaction was initiated by the addition of 20μL of 500μM substrate. The
reaction was stopped after 40 minutes by addition of 40μL malachite green reagent and the
absorbance was measured as previously described. Percentage of inhibition was calculated
using the following formula.
% inhibition ¼ 100ðpositive control  test wellÞ
positive control
ð4Þ
IC50 was determined using the following formula using Prizm software.
Y ¼ bottomþ ðtop bottomÞð1þ 10ðlogIC50xÞhill slopeÞ ð5Þ
Compound library
The compound library screened consisted of approximately 1400 small molecules, including
compounds approved by the Food and Drug Administration (FDA), a purified natural prod-
ucts library, and compounds purchased fromMaybridge Plc. (Cornwall, UK), Bionet Research
Ltd. (Cornwall, UK), Prestwick (Illkirch, France), and ChemBridge (San Diego, CA). Non-
FDA approved compounds were selected from the different vendors by applying a series of fil-
ters, including for clogP and predicted solubility. All small molecules tested generally adhere to
Lipinski’s rules (i.e., molecular weight<500, H-bond donors5, H-bond acceptors10, and
logP<5) and contain a low proportion of known toxicophores (i.e., Michael acceptors and
alkylating agents) and unwanted functionalities (i.e., imines, thiol, and quaternary amines) and
have been optimized to maximize molecular diversity. Compounds for HTS were stored as
DMSO stocks.
Results
Characterization of calcineurin enzyme activity
The active subunits of calcineurin is encoded by three different genes Aα, Aβ and Aγ. Aα is
predominantly expressed in brain [36,37]. Therefore, we purchased recombinant human CaN,
comprising CnAα and CnB subunits. A 19 amino acid peptide fragment (81-99aa), phosphory-
lated at the serine residue, from regulatory subunit type II of the CaN substrate cAMP-depen-
dent protein kinase (PKA) was used as the substrate [33]. This peptide fragment, called RIIP, is
a very well-established substrate for in vitro CaN activity assay. Initially, we determined the
optimal buffer composition for CaN activity. Enzyme activity was tested at pH values ranging
from 5 to 10 in 0.4-unit intervals, identifying an optimal pH of 7.0 (Fig 1a). It has been reported
that there is a binuclear metal center in the active site of CaN which binds to negatively charged
phosphate ions during the catalysis [38]. Therefore, we tested the effect of the bivalent metal
ions Mg2+ and Mn2+. Our results suggest that Mn2+ almost doubled the activity of activation
(Fig 1b), whereas the addition of Mg2+ (the enzyme stock already has 6mM) does not produce
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Fig 1. Characterization of enzyme activity. (a) In order to test the effect of pH on CaN activity, CaN assay was performed at different pH. Our data
suggested that pH 7 is optimum for CaN activity. To study the effect of bivalent metal ions on CaN activity, enzyme activity assays were performed at different
MnCl2 (b) and MgCl2 (c) concentrations. The data indicated that bivalent manganese increased CaN activity almost two times (b) whereas magnesium had
not effect (c). Note that (a), (b) and (c) were performed in absence of CM. (d) The concentration of CM which produces 50% activation (IC50 CM) of CaN was
determined by plotting initial reaction velocities at different Ca2+ and CM concentrations. Our data indicated that CM produces half maximumCaN activity at
1:1 molecular ratio. (e) Enzyme Km was determined by plotting initial velocity at different substrate (RIIP) concentrations. The Km was 213 μM. (f) DMOS
tolerance of the enzyme was assayed by performing the assay at different DMSO concentration ranging from, 0.125 to 4%. Our data indicate that at0.5%
DMSO did not alter enzyme activity. The assays were done in duplicate (except for experiment in Fig 1d) and the data were expressed as means and
standard error. The fittings were done using Prism software.
doi:10.1371/journal.pone.0131297.g001
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any effect (Fig 1c). However, we have not used more than 1mMMnCl2 in the assay to avoid
precipitation. CaN-CM binding is required for CaN activation. Since this activation step is
unique for CaN compared to other phosphatases, we decided to target both CaN-CM binding
site together with the catalytic site. However, saturating concentrations of CM in the assay
might mask the effect of a weak CaN-CM inhibitor. Thus, Ca2+ and CM were first titrated
simultaneously against CaN to determine the ratio of CaN/CM required for 50% enzyme activ-
ity. Our Ca2+/CM cross-titration study indicated that a molar ratio of 1:1 (CaN:CM) produces
50% activation of CaN in the presence of 500μMCa2+ (Fig 1d). Thus, all experiments were car-
ried out at 1:1 molar ratio of CaN/CM. Finally, we determined the Km value of CaN, using
phosphorylated RII peptide as substrate (RIIP) (Fig 1e). The Km value estimated under our
experimental conditions was 213 μM, which is very similar to previously published results [38].
However, we did observe significant substrate inhibition, which was not previously reported.
All of the compounds in the chemical library are solubilized in DMSO. Once all assay parame-
ters were characterized, we performed a DMSO tolerance test for CaN assay, which indicated
the enzyme activity, is not affected by0.5% and there is less than 5% inhibition at1%
DMSO(Fig 1f).
Miniaturization of the assay in 384 well format
After detailed enzyme characterization and standardization of reaction conditions, we con-
verted our malachite green based absorbance assay into a fluorescent quenching based assay
using a method previously described by Zuck and colleagues [34]. Maximum background fluo-
rescence emission of white 384 wells Perkin Elmer proxy plates at 610 nm was determined by
exciting the plate at different wavelengths (data not shown). The developing reagent malachite
green, upon binding inorganic phosphate, produces an intense green color, which absorbs at
610–620 nm. Thus, fluorescence emission of the plate is effectively absorbed by phospho-mala-
chite green complex. This quenching of fluorescence emission of the plate at 610 nm was used
for detection of phospho-malachite green complex. Next, the reading was converted into OD
using a previously described formula [34].
Reaction volume was titrated using a phosphate standard solution keeping concentration
constant (40 μM). Our data indicated that sensitivity increased with the reduction of the vol-
ume, with 5μL reaction volume producing the highest Z score of 0.38 (64 replicates in each
group) (Fig 2a). Although the Z score was not optimum yet we deliberately did not reduce the
reaction volume beyond 5μL since it is difficult for our robotic system to handle low volumes
accurately. Instead, we titrated the volume of the developing reagent malachite green, keeping
the reaction volume constant at 5μL. Sensitivity was increased by lowering the developing
reagent volume (Fig 2b). In fact, linear increase of Z score was observed with decreasing mala-
chite green volume finally yielding a Z score of 0.79 (64 replicates in each group) with 2.5μL
(Fig 2c). After standardizing the assay format, a phosphate standard curve was prepared (Fig
2d). Our data indicated that this assay is highly sensitive at low phosphate concentrations
(0.78–200 pmol), which cannot be achieved using a standard absorbance assay that has a detec-
tion limit of 31.25 pmol (Fig 2d).
Validation of the fluorescence-quenching assay
Once the technique was optimized using inorganic phosphate standards, we performed the
CaN phosphatase assay using previously optimized parameters with RIIP as a substrate. The
enzyme concentration and reaction time were meticulously determined to keep the product
concentration within the linear range of the detection. Using 272 replicates of full reaction and
80 replicates of no enzyme controls we have obtained a Z score of 0.63 (Fig 3a). To study
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further the fluorescence quenching assay format, we have tested endothall, a known inhibitor
of CaN. The IC50 of endothall determined by the fluorescence quenching assay was 12.63μM
(Fig 3b), which was very similar to previously published values [39], further validating the
assay format.
Fig 2. Miniaturization of the assay using phosphate standard. (a) The effect of different volumes of standard phosphate solution was studied by adding it
into 384 Perkin Elmer white proxy plates. The malachite green volume was kept at ratio of 1.25:1 (reaction volume: developing reagent volume). (b) The
influence of the malachite green quantity was measured using 200pmol phosphate in 5 μL volume. (c) Z score was plotted against malachite green volume. Z
score linearly decreases with malachite green volume. (d) A phosphate standard curve was generated using white plate fluorescence quenching versus
absorbance assay in 96 well plates. Inset shows high sensitivity phosphate detection at lower concentrations. Our data indicate that the 5μL assay volume
with 2.5μL developing reagent produces the optimum result using white proxy plates. In panels a and b, raw data was converted to OD and then % of
quenching was calculated.
doi:10.1371/journal.pone.0131297.g002
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Automation of the assay and hit generation
Next the assay was automated by mimicking all the liquid handling steps required for the HTS,
including reagent transfer from different source plates. 100% DMSO was used instead of the
compounds for standardization of the robotic handling. Enzyme concentration was titrated
using automated reagent handling in order to maximize the signal/background ratio staying
within the linear range of phosphate detection (data not shown). Next, two full plates were
tested at the determined concentration of the enzyme (7.5nM). The automated assay yielded a
Fig 3. Validation of the assay.White plate fluorescence assay was validated using CaN and a known
inhibitor. (a) Complete enzyme assay was performed in 272 replicates (full reaction) and compared with 80
replicates of no enzyme control. Assay was done manually in 384 well plates. The assay yielded a Z score of
0.63. (b) Endothall, a known inhibitor of CaN, was used to validate the assay format. The assay was done in
duplicate and the data point represents mean and standard error. IC50 was calculated by prism software,
using Eq 5, was 12.63μM.
doi:10.1371/journal.pone.0131297.g003
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Z’ score of 0.91 and 0.81 with %CV of 14 and 15 for plate 1 and plate 2, respectively (Fig 4a).
Since the automated assay fulfilled all the statistical criteria for HTS we performed a pilot
screen of 4 plates (about 1400 compounds tested at 10 μM final concentration) in duplicate.
The Z’ score of the duplicate plates were similar and ranged from 0.71 to 0.91 (Fig 4b). We
used a generous threshold of 50% inhibition to identify low potency inhibitors. The screening
Fig 4. Automation and screening. The complete assay was automated and performed in a similar way
mimicking all steps of the actual screening. 100%DMSOwas used to replace the compound. (a) Two full 384
plates were used. Plate 1 and 2 yielded a Z score of 0.91 and 0.81; % CV 13.99 and 15.12 for the full reaction,
respectively. (b) Z scores of 4 pilot plates screened in duplicate using this automated assay format.
doi:10.1371/journal.pone.0131297.g004
High Throughput Screening Assay for Calcineurin
PLOS ONE | DOI:10.1371/journal.pone.0131297 July 15, 2015 10 / 15
resulted in 16 hits from the 1400 compounds tested, producing a hit rate of 1.14%. Next, these
4 compounds were tested directly by using a 12 point dose-response using freshly purchased
stock from a commercial vendor. We selected these 4 compounds based on commercial
availability. Intrinsic fluorescence of the molecules can produce false positive results in our flo-
rescence quenching assay format. Therefore we have used regular 96 well format absorbance
based CaN assay to confirm the hits. 2 of these 4 compounds demonstrated moderate activity
with50% inhibition in a confirmatory assay. The IC50 values calculated from Prism software,
using a.4 parameter fit, were in the micro molar range (Fig 5a and 5b, and Fig 6) which is typi-
cal of hits identified from HTS. The chemical structure and formula of the hits are shown in
(Fig 6). Compound LDN-0013906 (tri-fluoperazine dihydrochloride), had an IC50 of 4.5μM
and was a previously identified CaN inhibitor [39,40] further validating the assay for HTS.
Discussion and Conclusion
Understanding the pathways by which misfolded proteins cause neurodegeneration and dis-
ease is essential to develop much needed efficient treatments for NDs. Recent exciting data in
various NDs have implicated hyper-activation of CaN in the cellular pathways leading to syn-
aptic loss and neuronal death [5,6,16,18,41]. Strikingly, administration of CaN inhibitors to
animal models of AD and TSEs appear to have therapeutic benefits [5]. The crystal structure of
calcineurin has been solved which should be useful for structure-activity relationship studies
and lead optimization processes. Therefore, CaN appears to be a promising drugable target
against NDs. Previously, CaN inhibition assays developed for so far for HTS were absorbance
based and lacked sensitivity [32,33]. In this article, we describe the development of a highly
reproducible, sensitive, and robust fluorescent read-out based assay for CaN activity which is
compatible with high throughput robotic screening.
We characterized the enzyme in our settings using a 96 well format and very carefully opti-
mized the effect with different conditions. Finally, we were able to convert an absorbance based
phosphatase assay into a highly sensitive, low volume, fluorescence read out based assay com-
patible with HTS. Although the concept of white plate fluorescent quenching was previously
described, it is not widely used for HTS screening, most likely due to some technical limita-
tions. In our study, we have addressed these limitations [42]. Deep yellow Malachite green
detection reagent itself quenches the background fluorescence of the plate in a dose-dependent
manner (data not shown). Although the quenching by malachite green alone is much lower
compared to the green phosphomolybdate complex, it may interfere with the sensitivity of the
assay. By carefully titrating the volume of malachite green we were able to detect as little as 780
fmol phosphate which is more than 30 times lower than the previously detected quantity [34].
Although very sensitive compare to the absorbance assay, in the low phosphate concentration
range (0.78–200 pmol) the assay completely saturates at 300 pmol phosphate. Therefore, cau-
tion has to be taken while determining the enzyme concentration and the reaction time. We
have shown, by scrupulous calculation of enzyme concentration and reaction times that even
12 point dose-responses can be performed using this format which reproduces the IC50 value
of a known inhibitor, endothall. The technique depends on the background fluorescence of the
assay plate material. However, by detailed characterization of the assay plate, we were able to
ensure reliability, which is reflected by the Z’ score of 0.85 and % CV15 of the automated
assay. Any fluorescent compounds with excitation/emission wavelength close to 573/610nm
are expected to produce false positives. However, use of a different detection assay as confirma-
tion of the hits (the absorbance based read-out), can easily rule out these possible false positive
candidates. Confirmed hits generated from our assay have IC50 values ranging from 4.5–
106.4 μM indicating that this platform can be used to screen inhibitors with wide range of
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potencies. The fact that one of the hits generated by our screening platform was a previously
known CaN inhibitor further validated the HTS assay. Our novel and highly reproducible,
inexpensive and sensitive HTS assay for identification of CaN inhibitors may be useful for the
discovery and development of compounds with therapeutic potential for various diseases,
including some of the most insidious NDs. Before therapeutic development, our early hits will
still need to be further validated in additional assays.
Fig 5. Validation of hits. Approximately 1400 compounds were screened, in duplicate, against CaN using
this assay format. 50% inhibition was set as the threshold to identify hits. Out of 16 hits identified, 4 were
selected on the basis of Lipinski's rule and commercial availability. Two of the selected compounds produced
a dose-dependent inhibition and at least more than 50% inhibition. The reaction was done in duplicate and
the data point represents mean and standard error. The IC50 were determined using Prism software, using Eq
5, and the values were (a) 106.4 μM for LDN-0013905 (flunarizine hydrochloride), (b) 4.5 μM for LDN-
0013906 (tri-fluoperazine dihydrochloride). The fact that tri-fluoperazine dihydrochloride (LDN-0013906) is a
known inhibitor of CaN further validated our assay format.
doi:10.1371/journal.pone.0131297.g005
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